• MG Respiratory Failure Requires Specific Treatments in the ER, Review Contends
  • FDA Grants Orphan Drug Status to Argenx’s ARGX-113 for Treating Myasthenia Gravis
  • Researchers Find ONX-0914 Halts Progression of Myasthenia Gravis in Animal Study
  • Scabies Skin Infestation Increases Risk of MG, Taiwanese Study Finds
  • Women with Myasthenia Gravis Report Lower Quality of Life than Male MG Patients, Study Finds
  • HanAll, Harbour BioMed Collaborate on Medicines for Myasthenia Gravis, Other Diseases
  • Rituxan Is Far Cheaper Than Other Therapy Options Over Myasthenia Gravis Patients’ Lifetimes, Study Shows
  • Soliris Keeps Improving Myasthenia Gravis Symptoms During Extension of Phase 3 Trial
  • Catalyst Readies Phase 3 Study of Firdapse in Patients with MuSK-MG
  • Myasthenia Gravis Patients See Moderate Improvement with Prograf, China Study Shows
  • Phase 2 Trial of ARGX-113, a Potential Therapy for MG, Is Still Enrolling Patients
  • Accordant’s Myasthenia Gravis Program Receives Disease Management Accreditation